Ali A. Alhadab

TL;DR: Examination of antifungal drug susceptibility in 198 clinical isolates collected from Kampala, Uganda, between 2010 and 2014 using the CLSI broth microdilution assay developed and validated an assay that could easily be implemented in a resource-limited setting, with similar susceptibility results.

TL;DR: Sertraline had faster cryptococcal CSF clearance, decreased IRIS, and decreased relapse compared with historical experiences, and this inexpensive and off-patent oral medication is a promising adjunctive antifungal therapy.

TL;DR: A population pharmacokinetic model was developed from clinical data collected in 34 pediatric patients and used in a simulation study to predict the population probability of various dosing regimens to achieve accepted safety and efficacy targets and an adaptive resistance PD model of Pseudomonas aeruginosa was built based on literature time-kill curve data.

TL;DR: Study findings indicate that sertraline PK is linear in healthy adult subjects at doses ≥ 50 mg, and exposures were nonlinear only after single oral doses <‬50 mg likely due to reduced bioavailability.

TL;DR: Predicted unbound sertraline concentrations at steady‐state in human tissues did not reach concentrations determined in vitro, indicating therapeutic doses of sertRALine are unlikely to produce concentrations required for anticancer and antimicrobial activities in humans.